Voyageur Pharmaceuticals Ltd.
VYYRF
$0.1285
$0.000.00%
OTC PK
| 05/31/2025 | 02/28/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -43.08% | 61.11% | |||
| Depreciation & Amortization | 0.00% | -33.33% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -43.06% | 61.02% | |||
| Operating Income | 43.06% | -61.02% | |||
| Income Before Tax | 32.24% | -71.41% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 32.24% | -71.41% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 32.24% | -71.41% | |||
| EBIT | 43.06% | -61.02% | |||
| EBITDA | 43.08% | -61.11% | |||
| EPS Basic | 35.14% | -54.17% | |||
| Normalized Basic EPS | 34.78% | -53.33% | |||
| EPS Diluted | 35.14% | -54.17% | |||
| Normalized Diluted EPS | 34.78% | -53.33% | |||
| Average Basic Shares Outstanding | 3.63% | 11.57% | |||
| Average Diluted Shares Outstanding | 3.63% | 11.57% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||